Does ActiPatch Work? What the Evidence Says
By Electrome Corporation · Published September 26, 2026
ActiPatch® has published evidence for pain relief, but a study result cannot predict your personal outcome. It is FDA 510(k) cleared (K192234) as an over-the-counter adjunctive treatment of musculoskeletal pain. Here is what the randomized trials, observational registries and clearance record can—and cannot—tell you.
What do the randomized trials report?
Bagnato and colleagues published a double-blind, placebo-controlled randomized trial in Rheumatology in 2016 involving people with knee osteoarthritis. The trial reported improvements in pain and function in its study population. The outcome is evidence concerning pain relief in that population; it is not proof that a wearable changes the underlying osteoarthritis or that every person with knee pain will benefit.
Brook and colleagues published a double-blind, placebo-controlled study in the Journal of Foot and Ankle Surgery in 2012 involving people with plantar fasciitis. The study reported a significant reduction in first-step morning heel pain versus placebo. That observation concerns pain, not resolution of the tissue condition. Study design, participant selection, follow-up period and measured outcomes all matter when applying a result to your situation.
What about neck and back pain evidence?
El Mohammad and colleagues reported an open-label randomized study in SN Comprehensive Clinical Medicine in 2021 comparing ActiPatch with etoricoxib for neck pain in 200 participants. Because treatment assignment was visible, expectations and other differences between groups may affect reported outcomes. Its design should not be described as a blinded placebo-controlled trial or a demonstration of superiority across treatments.
Staelin’s 2017 chronic back-pain registry describes people’s reported experience in routine use. It is observational, not randomized, and does not isolate the device effect from natural variation, expectations or other care. For chronic musculoskeletal pain more broadly, the Rawe and Kotak 2015 UK registry is also observational. These sources add context without replacing controlled trials.
What exactly does FDA clearance mean?
The relevant U.S. record is FDA 510(k) K192234. The clearance permits over-the-counter (OTC) marketing for adjunctive treatment of musculoskeletal pain. In this context, adjunctive means used alongside, not instead of, your established care. A 510(k) substantial-equivalence determination is distinct from FDA approval and should not be paraphrased as a promise of clinical benefit in an individual.
A label describing an indicated use is also not permission to claim that ActiPatch corrects a particular diagnosis. Discussions of knee osteoarthritis or plantar fasciitis on our site are about relief of associated musculoskeletal pain. The device is drug-free and nonthermal; these properties do not mean every user will tolerate it or find it useful.
Why can different users have different results?
People differ in the location, duration and source of their pain and in the other therapies they receive. Even a well-designed randomized study estimates an average result for its participants, not an individual forecast. If you use a device, record where you positioned it, how long you wore it and whether pain affected your daily activities. Discuss persistent or worsening symptoms with a clinician instead of relying on a product page for diagnosis.
Follow the package directions for placement and use. Position the loop over the painful musculoskeletal area, either directly on skin using included tape or a wrap, or over thin clothing; avoid thick fabric. Keep the device dry. Do not use it with a pacemaker or ICD, another implanted electronic device, or if you are pregnant or think you may be pregnant.
A practical reading of the evidence
The evidence supports a measured question: might adjunctive PSWT help with pain for someone like the participants studied? It does not support a blanket promise. Review the original publications and their methods, read the clearance record, and decide with your clinician how to assess your own experience. Our science page links to the underlying evidence and explains the difference between a trial and a registry.
Frequently asked questions
Is ActiPatch FDA approved?
No. ActiPatch is FDA 510(k) cleared under K192234 for over-the-counter (OTC) adjunctive treatment of musculoskeletal pain. Clearance and approval are distinct regulatory pathways.
Are the back-pain registry findings from an RCT?
No. Staelin’s 2017 chronic back-pain registry is observational and cannot alone establish a causal effect.
Will ActiPatch relieve my pain?
Individual results vary. Published studies describe their populations, not a guaranteed outcome for every person.
Primary sources
Educational information only. ActiPatch is FDA 510(k) cleared (K192234) for over-the-counter (OTC) adjunctive treatment of musculoskeletal pain. Read the package instructions and consult a clinician about persistent or worsening pain.